BiotechTube
NaDeNo

NaDeNo

Oslo, Norway· Est.
nadeno.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

NaDeNo is a private, preclinical-stage biotech leveraging a proprietary nanotechnology platform to overcome drug delivery hurdles for hydrophobic small molecules. Its core innovation involves locally administered, tissue-adhesive nanoparticles that anchor to target tissues, providing sustained local drug release and bypassing biological barriers. The company is advancing its lead asset, PACAB-002, for ovarian cancer and offers its platform for partnerships, recently securing an EIC Accelerator grant of up to €10 million to fund clinical development.

Oncology

Technology Platform

Proprietary polymeric nanoparticle platform for local drug delivery. Features tissue-adhesive nanoparticles for local retention and sustained drug release, designed to bypass biological barriers and minimize systemic toxicity. Uses a one-step, low-cost manufacturing process.

Opportunities

The high unmet need in ovarian cancer, particularly for treating peritoneal micrometastases, presents a clear clinical and commercial pathway for PACAB-002.
The platform's applicability to other locally administered drugs and disease areas offers significant expansion potential through partnerships with larger pharma companies.

Risk Factors

Key risks include the failure of preclinical results to translate into human clinical efficacy and safety, potential clinician resistance to a localized administration route, and intense competition in the nanomedicine space.
The company remains pre-revenue and will require significant additional funding beyond its current grant.

Competitive Landscape

NaDeNo competes in the crowded advanced drug delivery and nanomedicine sector, facing competition from both large pharmaceutical companies with internal capabilities and numerous biotech startups. Its differentiation lies in the specific tissue-adhesive mechanism for local retention and its emphasis on a simple, scalable manufacturing process.

More companies in Drug Delivery & Formulation →More companies in Norway →